CD274 and non-small cell lung carcinoma: A large multicenter cohort study of 1552 patients with advanced NSCLC who received PD-1/PD-L1 inhibitors showed that patients with a high TMB (>19.0 mutations per megabase) were associated with improved objective response rate (ORR), progression-free survival (PFS), and OS across all levels of PD-L1 TPS subgroups.